Rallybio (RLYB)
(Real Time Quote from BATS)
$1.11 USD
+0.01 (0.91%)
Updated Sep 25, 2024 01:40 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
RLYB 1.11 +0.01(0.91%)
Will RLYB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RLYB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RLYB
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock?
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
RLYB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Rallybio Corporation (RLYB) Could Rally 202.36%: Here's is How to Trade
Does Rallybio Corporation (RLYB) Have the Potential to Rally 290.63% as Wall Street Analysts Expect?
Down -19.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Rallybio Corporation (RLYB)
Other News for RLYB
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
Dr. Kush Parmar Steps Down from Rallybio’s Board and Committee
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
Buy Rating on Rallybio Stock Fueled by Promising RLYB212 Trial Outcomes and Potential FNAIT Treatment Breakthrough